MedAvail Holdings stock (US58406B1035): Pharmacy automation leader for retail investors

MedAvail Holdings develops and operates automated pharmacy kiosks designed for retail healthcare settings. The company's ZipScript platform enables touchless prescription filling, appealing to urgent care centers and pharmacies seeking efficiency. US investors track MedAvail for its role in expanding access to medications amid labor shortages in healthcare.

The stock traded at around $1.50 USD on OTC markets as of early 2026, according to Yahoo Finance as of 05/12/2026. Shares have faced volatility typical of microcap healthcare tech firms listed over-the-counter.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

MedAvail Holdings: core business model

MedAvail Holdings focuses on automating the pharmacy experience through self-service kiosks. The ZipScript stations allow patients to fill prescriptions without pharmacist intervention, using biometric verification and robotic dispensing. This model reduces wait times and operational costs for retail clinics, a growing segment in US healthcare.

Founded in 2013 and headquartered in Winnipeg, Canada, the company went public via SPAC merger in 2021. It targets partnerships with urgent care chains and independent pharmacies, with deployments in over 100 locations primarily in North America, per its investor presentations as of Q4 2025.

Main revenue and product drivers for MedAvail Holdings

Revenue stems from kiosk sales, installation fees, and ongoing service contracts. The ZipScript Pro model generates recurring income through per-script fees and maintenance subscriptions. In fiscal 2025, reported revenue reached $4.2 million for the year ended December 31, 2025, according to company filings as of 03/31/2026.

Key products include the ZipScript kiosk lineup, with expansions into chronic disease management modules. Growth depends on scaling deployments amid US retail clinic expansion, where chains like CVS MinuteClinic represent potential partners.

Industry trends and competitive position

The automated pharmacy sector benefits from US labor shortages, with pharmacist vacancies up 15% in 2025 per industry reports. MedAvail competes with larger players like ScriptPro and Parata Systems but differentiates via retail-focused, compact kiosks suitable for non-traditional pharmacy sites.

US retail clinics numbered over 3,000 in 2025, driving demand for integrated dispensing solutions. MedAvail's touchless tech aligns with post-pandemic hygiene preferences, positioning it for growth in underserved rural and suburban markets.

Why MedAvail Holdings matters for US investors

MedAvail's US-focused deployments expose it to the $500 billion US pharmacy services market. OTC listing provides access for retail investors interested in healthcare automation without NYSE minimums. Its Canadian base offers tax treaty benefits for cross-border holdings.

Conclusion

MedAvail Holdings operates in a niche poised for expansion as retail healthcare grows. Its kiosk technology addresses key pain points in prescription fulfillment. Investors monitor deployment growth and partnerships for signs of scaling, while noting microcap risks inherent to OTC-traded names.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.